Member May 2025: Update on Medications for Patients with Brain Injury: Reviewing Best Practices Using a Case Study Approach (1.25 CME) (On Demand)-Session Recording

Video Transcription

Video Summary

In a recent session for Member May, medical professionals discussed medications for patients with brain injuries using a case study approach. The session emphasized best practices and updates in managing such patients, beginning with a foundational overview of neurotransmitters. Key neurotransmitters include acetylcholine, norepinephrine, dopamine, serotonin, glutamate, and GABA—each with specific roles and affected pathways in brain injury. The discussion highlighted a case of an 18-year-old male with a brain injury, following an ATV crash, who developed complications like paroxysmal sympathetic hyperactivity (PSH) and disorders of consciousness. Management strategies for PSH were detailed, including using medications like propranolol, clonidine, baclofen, bromocriptine, and gabapentin, tailored to the specific symptoms presented by the patient.<br /><br />Transitioning into disorders of consciousness treatments, the session delved into awakening agents, with Amantadine being a primary drug choice. Other agents such as Zolpidem, bromocriptine, methylphenidate, and more were discussed regarding their efficacy and recent research insights. The panel emphasized personalized treatment plans considering individual patient histories, symptoms, and prior medication use, particularly in cases involving ADHD.<br /><br />Attention was also given to weaning off these medications during rehab or outpatient follow-up, highlighting the importance of monitoring for signs of regression or side effects. The session fostered a dynamic discussion on combining therapies, side effects, and the use of these medications alongside returning to school or work. This comprehensive examination underscored the importance of a tailored, patient-centric approach in brain injury pharmacotherapy.

Keywords

brain injury

neurotransmitters

paroxysmal sympathetic hyperactivity

disorders of consciousness

personalized treatment

propranolol

amantadine

case study

pharmacotherapy

rehabilitation

medical professionals